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Abstract
Background
Surgical sutures can promote migration of bacteria and thus start infections. Antiseptic coat-
ing of sutures may inhibit proliferation of adhered bacteria and avoid such complications.
Objectives
This study investigated the inhibition of viable adhering bacteria on novel antimicrobially
coated surgical sutures using chlorhexidine or octenidine, a critical factor for proliferation at
the onset of local infections. The medical need, a rapid eradication of bacteria in wounds,
can be fulfilled by a high antimicrobial efficacy during the first days after wound closure.
Methods
As a pretesting on antibacterial efficacy against relevant bacterial pathogens a zone of inhi-
bition assay was conducted with middle ranged concentrated suture coatings (22 μg/cm).
For further investigation of adhering bacteria in detail the most clinically relevant Staphylo-
coccus aureus (ATCC®49230™) was used. Absorbable braided sutures were coated with
chlorhexidine-laurate, chlorhexidine-palmitate, octenidine-laurate, and octenidine-palmitate.
Each coating type resulted in 11, 22, or 33 μg/cm drug content on sutures. Scanning elec-
tron microscopy (SEM) was performed once to inspect the coating quality and twice to
investigate if bacteria have colonized on sutures. Adhesion experiments were assessed by
exposing coated sutures to S. aureus suspensions for 3 h at 37˚C. Subsequently, sutures
were sonicated and the number of viable bacteria released from the suture surface was
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determined. Furthermore, the number of viable planktonic bacteria was measured in sus-
pensions containing antimicrobial sutures. Commercially available sutures without drugs
(Vicryl®, PGA Resorba®, and Gunze PGA), as well as triclosan-containing Vicryl® Plus were
used as control groups.
Results
Zone of inhibition assay documented a multispecies efficacy of novel coated sutures against
tested bacterial strains, comparable to most relevant S. aureus over 48 hours. SEM pictures
demonstrated uniform layers on coated sutures with higher roughness for palmitate coatings
and sustaining integrity of coated sutures. Adherent S. aureus were found via SEM on all
types of investigated sutures. The novel antimicrobial sutures showed significantly less via-
ble adhered S. aureus bacteria (up to 6.1 log) compared to Vicryl® Plus (0.5 log). Within
11 μg/cm drug-containing sutures, octenidine-palmitate (OL11) showed the highest number
of viable adhered S. aureus (0.5 log), similar to Vicryl® Plus. Chlorhexidine-laurate (CL11)
showed the lowest number of S. aureus on sutures (1.7 log), a 1.2 log greater reduction. In
addition, planktonic S. aureus in suspensions were highly inhibited by CL11 (0.9 log) repre-
sents a 0.6 log greater reduction compared to Vicryl® Plus (0.3 log).
Conclusions
Novel antimicrobial sutures can potentially limit surgical site infections caused by multiple
pathogenic bacterial species. Therefore, a potential inhibition of multispecies biofilm forma-
tion is assumed. In detail tested with S. aureus, the chlorhexidine-laurate coating (CL11)
best meets the medical requirements for a fast bacterial eradication. This suture coating
shows the lowest survival rate of adhering as well as planktonic bacteria, a high drug release
during the first–clinically most relevant– 48 hours, as well as biocompatibility. Thus, CL11
coatings should be recommended for prophylactic antimicrobial sutures as an optimal surgi-
cal supplement to reduce wound infections. However, animal and clinical investigations are
important to prove safety and efficacy for future applications.
Introduction
Surgical site infection (SSI) rates vary in the range of 2% to 20% depending on the chosen type
of surgical procedure [1–4]. SSI generally poses a risk for patients due to an increased morbidity
and even mortality [4]. Affected patients often need further surgical intervention leading to
higher cost for the health care system [1, 5]. Several factors are involved in the onset of SSI, one
of which is the surgical suture itself. The presence of foreign material highly reduces the critical
number of bacteria facilitating a clinically relevant infection [6–8]. Furthermore, the capillarity
of sutures supports the path of bacteria into wounds by soaked fluids. This so-called “wicking
effect” triggers such infections. [9] Especially, the type of material and structure of surface deter-
mine the ability of bacteria to adhere and induce infections [9]. In this context, the number of
viable adhered bacteria is considered an essential trigger for SSI related to suture material. The
main issues are proliferation of attached bacteria and formation of persistent biofilms [9–11].
Once a biofilm has developed, it protects bacteria against the host’s immune system as well as
systemically [12, 13] and locally applied antibiotics.
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
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A possible solution to prevent suture-associated site infections is the use of antimicrobially
coated sutures. These sutures can be used to inhibit viable adhered microbes and thus prevent
biofilm formation. Clinical indications for antimicrobial sutures may be infection prophylaxis in
susceptible patients (e.g. immunosuppression) and especially in surgical procedures with elevated
risk of infection (e.g. contaminated surgical site). To our knowledge, so-called “Plus” sutures con-
taining triclosan are the only antimicrobial sutures currently available on the European market.
A systematic literature review on antimicrobial sutures by Chang et al. identified seven ran-
domized clinical trials finding no significant reduction of local infections by means of these
materials [14]. However, these studies did not fulfill the recommended standards for meta-
analyses [15]. In contrast, the latest independent meta-analyses indicate a beneficial use of
antimicrobial sutures for wound closure containing triclosan [16, 17]. Due to this data, antimi-
crobial sutures are highly recommended as a supplementary step to reduce the risk of SSI [15].
Further studies showed high efficacy and cost reduction of antimicrobial sutures for infection
prevention [18–22] and could clarify which indication benefits most from the use of available
antimicrobial sutures [23, 24].
Apart from promising study results of triclosan-coated sutures, triclosan also has drawbacks
including formation of toxic side products (e.g. chlorinated phenols, methyl triclosan) [25]
and antibiotic resistances [26, 27], likely due to its prevalence in cosmetics and soap products
[28, 29]. Additionally, triclosan promotes the protein mediated binding of staphylococci to
host cells with the consequence of an increased number of nasal infections caused by S. aureus
colonization in the presence of triclosan [30]. Due to these restrictions in the use of triclosan,
alternatives are urgently needed. Chlorhexidine and octenidine are highly effective alterna-
tives, inhibiting relevant pathogens of wound infections. Both antiseptics have a broad antibac-
terial spectrum as well as high biocompatibility indices [31–33]. Chlorhexidine is routinely
used in oral surgery [31]. In combination with silver, chlorhexidine is also used for the antimi-
crobial protection of hernia meshes. These chlorhexidine meshes show antibacterial efficacy,
safety and high tissue integration [34]. Octenidine is a clinically well-established skin and
wound antiseptic solution and does not seem to select for resistance [35].
Chlorhexidine and octenidine have similar mechanism of action: Positively charged drug
molecules bind to negative charges on bacterial cell walls, leading to membrane leakages and
finally cell death [36, 37]. Both antiseptics are effective against the most gram-negative and
gram-positive bacteria [37, 38], including the most clinically relevant pathogen genus staphylo-
cocci, causing wound and nosocomial infections [39, 40]. In order to support wound healing,
a fast and if possible complete eradication of bacteria inside wounds after surgery is necessary.
Therefore, administration of antimicrobial agents is recommended at high dosages and short
time periods for prophylaxis to avoid formation of resistant bacteria [41, 42].
Antimicrobial sutures must fulfill a balancing act between inhibiting bacteria and sustain-
ing biocompatibility to the healing wound consisting of eukaryotic tissue. In former studies,
we adjusted the drug concentration dependent on efficacy and biocompatibility of novel anti-
microbial suture coatings containing chlorhexidine diacetate [43] or octenidine dihydrochlor-
ide [44]. These studies used coatings based on fatty acid carriers to achieve delayed drug
release systems and to sustain bacterial inhibition zones in vitro.
The aim of the present study was to investigate the effectiveness of novel chlorhexidine- or
octenidine-coated sutures against adherent bacteria. At first, a zone of inhibition assay was
conducted to determine the efficacy against several relevant pathogenic bacteria. Then, in
order to investigate the effects of novel antimicrobially coated sutures on viable adhering bac-
teria in detail the clinically most relevant S. aureus was used. Therefore, coated suture samples
were exposed to S. aureus suspensions. Scanning electron microscopy (SEM) was performed
to inspect suture coatings before and adherent bacteria after S. aureus exposure. The viability
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
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of bacteria adhered on sutures was investigated after sonication. In addition, the viability of
planktonic bacteria in the surrounding of coated sutures was measured. The tested novel
coated sutures were compared to commercially available absorbable sutures without any drug
cover as well as triclosan-containing Vicryl1 Plus sutures.
Materials and methods
Surgical sutures
In this study, uncoated braided absorbable—polyglycolic acid—suture Gunze (G: Gunze PGA,
Kyoto, Japan) of 0.4 mm in diameter, corresponding to the United States Pharmacopeia stan-
dard USP1, was used to produce antimicrobial sutures by coating. Suture controls were com-
mercial PGA Resorba1 (R: Resorba, Nu¨rnberg, Germany), Vicryl1 and triclosan-containing
Vicryl1 Plus (V and VP, respectively: Ethicon, Norderstedt, Germany). Furthermore, Gunze
PGA sutures only coated with fatty acids—palmitic acid (PA80) and lauric acid (LA80)—were
tested to investigate potential effects of drug carriers only.
Antimicrobial suture preparation using chlorhexidine and octenidine in
fatty acid carriers
The formulation of coating solutions and the reproducibility of the dip coating process for
antimicrobial coating of absorbable PGA sutures (Gunze) was described earlier in one of our
studies for chlorhexidine diacetate [43] and octenidine dihydrochloride [44] based on fatty
acids as drug carriers. These coating procedures resulted in an average coating weight of 2.2
mg ± 0.2 mg (n = 10) for 40 cm braided, absorbable sutures (USP1) [43, 44].
In the present study, four coating types were compared: Chlorhexidine in lauric acid (CL)
or palmitic acid (CP) and octenidine in lauric acid (OL) or palmitic acid (OP). For each type
of suture coating, three different solutions with defined concentrations of active agents were
formulated. To obtain preparation solutions, antiseptic drugs and fatty acid carriers (palmitate
or laurate) were dissolved in 99.8% ethanol with a total mass content of 5% (w/w). Sutures
were dipped in these sterile coating solutions for 2 min, followed by a drying period of 2
hours. Then, the weight of coatings on sutures was measured via a precision balance (Atilon
ATL-224, Acculab, Bradford, USA) and the resulting drug concentration per unit of length
was calculated. This procedure generates antimicrobial sutures with 11 μg/cm, 22 μg/cm and
33 μg/cm for both chlorhexidine- and octenidine-containing sutures. An overview of the tested
novel antimicrobial sutures and their coating composition for this study is given in Table 1.
Table 1. Overview of the prepared novel antimicrobially coated sutures.
A) chlorhexidine-coated sutures B) octenidine-coated sutures C) fatty acid carrier
types of chlorhexidine coating drug content (μg/cm) types of octenidine coating drug content (μg/cm) content (μg/cm) ratio (%)
chlorhexidine-laurate CL11 11 octenidine-laurate OL11 11 44 80
chlorhexidine-palmitate CP11 octenidine-palmitate OP11
chlorhexidine-laurate CL22 22 octenidine-laurate OL22 22 33 60
chlorhexidine-palmitate CP22 octenidine-palmitate OP22
chlorhexidine-laurate CL33 33 octenidine-laurate OL33 33 22 40
chlorhexidine-palmitate CP33 octenidine-palmitate OP33
Chlorhexidine-coated sutures (A) and octenidine-coated sutures (B) and their coating compositions are shown in detail. For both types of sutures, the amount of
antimicrobial substance per length of sutures after preparation resulting from a mean coating weight of 40 cm suture samples at 2.2 ± 0.2 mg (n = 7) is given.
Additionally, the fatty acid content and ratio (C) is referred to the total weight of coating mass per cm length of the sutures.
https://doi.org/10.1371/journal.pone.0190912.t001
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In comparison to our chlorhexidine- or octenidine-containing antimicrobial sutures, the
Vicryl1 Plus control group suture contains 2.7 μg/cm triclosan within the European Union
[29].
Antimicrobial efficacy against multiple relevant pathogenic bacteria
In order to achieve information about a multispecies efficacy Staphylococcus aureus
(ATCC149230™), a methicillin-resistant S. aureus strain—short MRSA (ATCC143300™),
Staphylococcus epidermidis (ATCC135984™), Enterococcus faecalis (ATCC129212™) and
Escherichia coli (ATCC125922™) was used for general antibacterial suture tests. The zone of
inhibition assay was conducted over a period of 48 hours to compare the species-dependent
efficacy of each suture type using the middle ranged drug concentration in the amount of
22 μg/cm. Therefore, coated suture samples were placed on bacterial lawns on Agar plates
(Mueller Hinton II), inoculated with a bacterial suspension at an optical density of 0.1 at 600
nm. Plates with samples were incubated over night at 37˚C, then zones of inhibition were mea-
sured in tenths of a millimeter and coated suture samples were transferred to newly inoculated
Agar plates. This process was repeated twice for two days. A more detailed description of the
zones of inhibition assay is given in literature [43].
Scanning electron microscopy (SEM) for structural analysis of coated
sutures
In order to inspect quality of suture coatings as well as integrity, SEM pictures were taken
without bacterial exposure at lower magnifications (up to 200x) to achieve an overview per-
spective. For this purpose, novel antimicrobially coated sutures, as well as uncoated and com-
mercially available suture samples were prepared for common SEM. During preparation of
suture samples, gold was sputtered on the suture samples at 5 x 10−2 mbar two times for 40 sec
each with a Bal-tec Med020 coating system (Bal-tec, Balzers, Liechtenstein). Hereby, a thin
gold layer of approximately 28 nm was generated improving image quality by generating con-
ductive surfaces and protecting biological objects [45]. Pictures were taken for this investiga-
tion using a low vacuum SEM type JSM 6060LV (JEOL, Freising, Germany). Regarding the
thermally labile suture—consisting of PGA—a low acceleration voltage of 5 kV was chosen.
Scanning electron microscopy (SEM) for visualization of adherent bacteria
Additionally, SEM inspections were executed at higher magnification (2,500x) to investigate
bacteria adherence on coated suture samples after bacterial exposure. SEM investigations were
performed after washing of inoculated sutures, and before sonication. The number of adhered
bacteria was estimated by using the field of view from SEM pictures (approximately 50 x
50 μm2) and counting visible adhering bacteria. The mean of three pictures from three sutures
was calculated. Semi-quantitative levels for adhered bacteria were defined (low: up to 50 bacte-
ria, moderate: 50 to 200 bacteria, and high: > 200 bacteria). Suture samples exposed to bacteria
were treated with 4% paraformaldehyde in 0.01 M pbs solution for at least 1 h. This fixation
step stabilizes the biological structure of the attached bacteria by cross-linking of proteins [46]
and simultaneously inactivating bacteria. Subsequently, bacteria-containing suture samples
were dried, gold sputtered as described and investigated by SEM.
Viability of adhered bacteria on coated sutures (bacterial adhesion assay)
To quantitatively investigate the influence of antiseptic suture coatings on the viability of
adhered bacteria, coated and uncoated suture samples were inoculated in bacterial suspensions
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
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for 3 h at 37˚C using Staphylococcus aureus (ATCC149230™). Attached viable S. aureus num-
bers on suture samples were measured after sonication and incubation of detached bacteria.
Viable bacteria were determined by growth on Mueller Hinton II Agar plates (MHA; BD Diag-
nostic Systems, Heidelberg, Germany) and counting of colony-forming units (cfu). The bacte-
rial adhesion assay described by Gollwitzer et al. [18, 47] was modified using the following
procedure:
Mueller Hinton Broth (MHB; BD Diagnostic Systems, Heidelberg, Germany) was used to
cultivate bacteria in suspension. Bacterial concentration was adjusted with a biophotometer
(Eppendorf, Hamburg, Germany) at a wavelength of 600 nm. Suture samples of 1 cm in length
(n = 10) were put in 1.5 ml-tubes filled with 1 ml S. aureus suspension at an initial concentra-
tion of 1.3 x 108 cfu/ml (OD600 = 0.1). The tubes were incubated in a thermo-shaker (Unimax
1010, Heidolph Instruments, Schwabach, Germany) for 3 h at 37˚C while shaking at 200 rpm.
To remove weakly adhered bacteria from sutures, a washing process involving dipping the
sutures 3 times in 1 ml sterile isotonic saline (0.9%) was performed. Subsequently, to remove
strongly adhered bacteria from suture surfaces, samples were put into tubes with 1 ml sterile
0.01 M phosphate buffered saline (pbs: NaCl 0.138 M, KCl 0.0027 M; pH 7.4; P3818, Sigma-
Aldrich, Germany) and treated using a 3-step procedure: (1) vortexing for 10 sec, (2) sonica-
tion for 1 min using an ultrasound at 35 kHz/280W (Sonorex RK255H, Bandelin, Berlin, Ger-
many), and (3) vortexing for 10 sec. The obtained bacterial suspension was diluted to 1:10,
1:100, 1:1,000, and 1:10,000 with sterile 0.01 M pbs, and 100 μl of each dilution were plated in
double on MHA plates. After 24 h of incubation at 37˚C, colony-forming units were counted
and the number of viable adhered bacteria on the suture surfaces was calculated. The numbers
obtained were compared to those obtained from the following references: uncoated PGA
suture (Gunze), palmitic and lauric acid coatings (PA80, LA80), commercially available
absorbable sutures (Vicryl1 and PGA Resorba1) with fatty acid coating, and triclosan-
coated sutures (Vicryl1 Plus). For all determined numbers of viable adhered bacteria a loga-
rithmic reduction was calculated referred to the uncoated Gunze suture (G). Significance tests
were compared in general to uncoated Gunze (G) and especially for antimicrobially coated
sutures to the commercial antimicrobial suture Vicryl1 Plus (VP).
Viable bacteria of suspensions after suture incubation
To investigate potential growth inhibition on suture-surrounding bacteria in planktonic form,
antimicrobial sutures were incubated for 3 h in S. aureus suspensions followed by detecting
viable numbers of bacteria. Therefore, suture samples at 1 cm length were incubated in S.
aureus suspensions during the viability adhesion assay experiments as described above. The
turbidity of the bacterial suspension was measured at 600 nm (OD600) using a biophotometer
(Eppendorf, Hamburg, Germany) for each inoculated suture at the beginning and at the end
of experiment after 3 h. Numbers of viable bacteria were determined via a calibration curve for
the bacterial test strain. The number of viable planktonic bacteria was compared to the bacte-
rial growth in the presence of uncoated Gunze suture (G) and a logarithmic reduction was cal-
culated after 3 hours of incubation for each suture sample.
Evaluation of results of 11 μg/cm drug-containing sutures in regard to
former studies
To determine the best novel antimicrobial suture for medical need, we evaluated the 11 μg/cm
drug-containing novel chlorhexidine- and octenidine-coated sutures (CL11, CP11, OL11, and
OP11) in comparison to the antimicrobial control Vicryl1 Plus (VP). Results of the present
study as well as from former studies [43, 44] were taken into account for comparative
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
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evaluation. Thus, for each relevant aspect (viability of bacteria adhered or in suspension, num-
bers of bacteria detected via SEM, biocompatibility, drug release kinetics and efficacy in zone
of inhibition tests), semi-quantitative levels were defined.
Statistics
Mean values and standard deviations were calculated from at least five independent measure-
ments. Student’s t-test was performed for testing on equality of data sets at significance levels
p< 0.05 (), p< 0.01 (), and p< 0.001 (). The distribution of data was checked for each
group referred to the mentioned controls via F-Test in Microsoft Excel1 2013. These results
were taken into account during the student’s t-test. The Gaussian error propagation law was
used for the subsequent use of flawed values. GraphPad Prism 6.0 (GraphPad1 Software, La
Jolla, CA, USA) was used for data evaluation and visualization of the result graphs.
Results
Antimicrobial efficacy against multiple relevant pathogenic bacteria
In general, high antimicrobial efficacy was found for all of the tested bacterial strains over the
relevant test period of 48 hours (Fig 1). The type of coating affected the sizes of inhibition
zones, especially the type of coated drug. On average, chlorhexidine-coated sutures inhibited
bacteria at 8.3(±1.4) mm and octenidine-coated sutures at 2.3(±0.5) mm after 24 hours. After
48 hours, the inhibition zones were on average 8.2(±1.7) mm and 1.7(±0.4) mm for chlorhexi-
dine and octenidine coatings, respectively. The antibacterial efficacy of novel coated sutures
against tested bacterial strains was comparable to the most relevant bacterial strain S. aureus,
used for further detailed investigations on bacterial adhesion.
Scanning electron microscopy (SEM) for structural analysis of coated
sutures
Novel coated sutures show sustaining integrity and uniformly covered surfaces by drug-con-
taining coating layers. There are hardly detectable differences via SEM for suture coatings
using concentrations at 11 μg/cm, 22 μg/cm and 33 μg/cm. Therefore, sutures with the lowest
and highest drug concentrations (11 μg/cm and 33 μg/cm) are presented (Fig 2, left). The ref-
erence suture (G) shows the structure of the uncoated suture material used for preparing anti-
microbial sutures. Both drug carrier preparations (palmitic acid and lauric acid) completely
covered the suture surface. The lauric acid-containing coatings CL11, OL11, CL33, and LA80
sutures showed smooth surface layers around each single filament. In contrast, a rougher
structure of palmitic acid-containing coatings CP11, OP11, CP22, and PA80 was a characteris-
tic feature. In general, the surface roughness of palmitate using novel coated sutures was com-
parable to commercially available sutures such as Vicryl1 Plus, Vicryl1, and PGA Resorba1
(Fig 2, right).
Scanning electron microscopy (SEM) for visualization of adherent bacteria
In particular, the antimicrobial control (VP), the commercial triclosan-coated suture Vicryl1
Plus showed relatively high numbers of adhering bacteria. All tested novel antiseptic coated
sutures (CL11, CP11, OL11, and OP11) showed numerous bacteria on their surfaces (Fig 3:
left), even for sutures at higher drug concentrations (CL33, CP33, OL33, and OP33). Numer-
ous adhering bacteria were detectable on the non-antimicrobial suture control (G) and other
sutures without antimicrobial substances (Fig 3: right; LA80, PA80, V, R, and G). Especially,
inside gaps between single filaments, a high accumulation of S. aureus colonies was found on
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
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top of the fine coatings of lauric acid components as well as on the rough lumps of palmitic
acid coatings.
Viability of adhered bacteria on coated sutures (bacterial adhesion assay)
Chlorhexidine-laurate suture (CL11) shows the lowest numbers of viable adhered bacteria
within the 11 μg/cm drug-containing novel coated sutures. Compared to the antimicrobial
control Vicryl1 Plus, CL11 shows a 1.2 log greater reduction. In general, chlorhexidine and
octenidine coatings exhibit lower colony numbers of viable adhered S. aureus, as compared to
the non-antimicrobial control (G). The number of viable adhered bacteria of each novel anti-
microbially coated suture type (CL, CP, OL, OP) and Vicryl1 Plus (VP) was statistically sig-
nificantly reduced (p< 0.001: ; Fig 4) compared to sutures without active substances
(PA80, LA80, V, R, and G). In comparison to the triclosan-containing suture (VP), represent-
ing the antimicrobial suture control, the novel sutures showed an even more significant reduc-
tion of viable adhered bacteria (p< 0.001: ; CL11-CL33, CP11-CP33, OL11, OL33, OP22,
Fig 1. Zone of inhibition assay for five bacterial species over 48 hours. Zones of inhibition in millimeter for each
coating type at 22 μg/cm drug content (CL22, CP22, OL22, OP22) on sutures. Test strains used were S. aureus, MRSA, S.
epidermidis, E. faecalis and E. coli after A) 24 hours and B) 48 hours test period.
https://doi.org/10.1371/journal.pone.0190912.g001
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and OP33) and (p< 0.05: ; OL22). Adhered bacteria were slightly inhibited by OP11 (n.s.),
comparable to Vicryl1 Plus. The reduction of viable adhered bacteria (Fig 4) was expressed
by a logarithm of the basis 10, calculated for each tested suture. Bacterial log reductions were
calculated referred to uncoated Gunze suture (G) without any drug. Significance tests were
referred to the control (G), and on the other hand to triclosan-coated Vicryl1 Plus suture
(VP). Chlorhexidine- and octenidine-coated sutures demonstrated a high log10 reduction of
adhered S. aureus colonies in the range of 0.5 (OP11) up to 6.1 (OL33) compared to uncoated
Gunze suture (G). In contrast, triclosan-containing Vicryl1 Plus suture demonstrated a small
0.5 log reduction against adhering bacteria.
Viable bacteria in suspensions after suture incubation
The reduction of planktonic bacteria in suspensions within the 11 μg/cm drug-containing
novel antimicrobial sutures is lowest for the chlorhexidine-palmitate (CP11) and laurate
sutures (CL11). Compared to the antimicrobial control Vicryl1 Plus, CP11 and CL11 showed
a greater bacterial reduction of 0.7 log and 0.6 log, respectively. In general, suspension bacteria
were highly inhibited by the novel bactericidal sutures (Fig 5), whether coated with chlorhexi-
dine or octenidine for each used concentration. Bacterial reductions were referred to the non-
Fig 2. SEM pictures prior to bacterial exposure to inspect coating quality and suture integrity (magnification
200x). Left: Chlorhexidine- and octenidine-coated sutures for the lowest and highest drug concentrations used.
Chlorhexidine sutures (CL11, CL33, CP11, and CP33) and octenidine-coated sutures (OL11, OL33, OP11, and OP33)
are shown for laurate or palmitate carriers. Commercial antimicrobial sutures Vicryl1 Plus (VP). Right: Reference
sutures without antimicrobial drugs. Plain PGA suture material Gunze used for preparations (G) and commercially
available resorbable sutures PGA Resorba1 (R) and Vicryl1 (V). Furthermore, sutures coated solely with fatty acid
lauric acid (LA80), or palmitic acid (PA80) were investigated. Images are representative of three numbers of fields
from three suture replicates.
https://doi.org/10.1371/journal.pone.0190912.g002
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antimicrobial suture control (G), showing similar unaltered bacterial growth in suspensions
similar to other tested sutures without antimicrobial substances (PA80, LA80, V, and R). In
comparison to uncoated Gunze (G), Vicryl1 Plus (VP) showed a bacterial reduction of 0.3
log, comparable to OL11 and OL22. Tested chlorhexidine-coated sutures decreased bacteria in
suspension even further (p< 0.001: ; CL11-CL33 and CP11-CP33) with at least 0.9 log. In
addition, most of the octenidine sutures also showed a higher reduction of suspension bacteria
compared to (G): OP11 (0.5 log), OL33 (1.0 log), OP22 (1.0 log), and OP33 (0.9 log).
Evaluation of results of 11 μg/cm drug-containing sutures in regard to
former studies
The chlorhexidine-laurate sutures (CL11) best met medical requirements. CL11 shows the
lowest number of viable bacteria on sutures, a high drug release within the first 48 h, as well as
good biocompatibility. Potentially, each of the four novel coated sutures using 11 μg/cm drug
concentration can be clinically applied, since they are antimicrobial effective over several days
and biocompatible [43, 44]. The experimental data from the current study (Table 2: white
background) and earlier studies [43, 44] (Table 2: blue, orange and light gray background)
Fig 3. SEM pictures following bacterial exposure of coated sutures to visualize adhered bacteria and estimate their
number semi-quantitatively (magnification 2,500x). Sutures were incubated in S.aureus suspension at 1.3 x 108 cfu/
ml for 3 hours. Left: Novel antimicrobially coated sutures are shown for the lowest and highest drug concentrations at
11μg/cm and 33μg/cm, respectively. Chlorhexidine-coated sutures (CL11, CL33, CP11, and CP33) and octenidine-
coated sutures (OL11, OL33, OP11, and OP33) depicted for laurate or palmitate carriers. The commercial
antimicrobial triclosan reference Vicryl1 Plus (VP) is also shown in the last row. Right: Suture references without
antimicrobial substances (G, R, LA80, PA80, and V). Adhered bacteria were exemplarily marked with an asterisk ().
Images are representative of three numbers of fields from three suture replicates.
https://doi.org/10.1371/journal.pone.0190912.g003
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were compared to each other. The rating levels (+, ++ and +++) used for the comparison of
antimicrobial sutures are declared in Table 3.
The recent data demonstrated that chlorhexidine-laurate suture (CL11) shows the most
efficient inhibition of adhered bacteria, which is critical for local infections. Therefore, we rec-
ommend the CL11 suture compared to Vicryl1 Plus as an optimal surgical supplement to
reduce wound infections. Nevertheless, octenidine-containing sutures at 11 μg/cm can also be
helpful in applications where a slower and longer lasting drug release should be necessary.
Discussion
In this study, we found that novel antimicrobial sutures using chlorhexidine or octenidine
coatings were effective against multiple bacterial pathogens. Especially, viable adhering and
surrounding planktonic S. aureus were strongly inhibited. Additionally, we found that reduc-
tion of adherent bacteria via novel sutures could be up to 12-fold higher than achievable with
commercial antimicrobial suture Vicryl1 Plus using triclosan. Scanning electron microscopy
(SEM) pictures were used to investigate suture coatings and to demonstrate bacterial adhesion.
The main finding of the present study was that novel antimicrobially coated sutures show
Fig 4. Numbers of adhered S. aureus colonies on sutures’ surfaces per cm sample after 3 hours of incubation in on average 1.3 x 108 cfu/ml bacterial
suspension. Viably adhered numbers of bacteria and their reductions compared to uncoated Gunze (G) suture. Left (up to dashed line): Sutures coated with
antimicrobial substances, such as chlorhexidine-laurate (CL), chlorhexidine-palmitate (CP), octenidine-laurate (OL), and octenidine-palmitate (OP) each
with the drug concentration 11, 22, and 33 μg/cm. Novel coated sutures were also compared to commercially available triclosan-containing Vicryl1 Plus
(VP) suture. Right: Groups of sutures without active antimicrobial agents, uncoated Gunze (G), coated with fatty acids (PA80, LA80) and commercially
available common resorbable sutures (V: Vicryl1, R: PGA Resorba1). Significance levels are p<0.05 (), p<0.01 () and p<0.001 (); n.s.: not
significant, n.a.: not applicable.
https://doi.org/10.1371/journal.pone.0190912.g004
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Fig 5. Numbers of viable bacteria in suspension incubated for 3 hours with novel antimicrobial sutures. An initial S. aureus concentration of 1.3 x 108 cfu/ml
was used for bacterial suspensions. Chlorhexidine- or octenidine-coated sutures showed a strong inhibition of pathogens in the surrounding suspensions. The
triclosan-coated suture Vicryl1 Plus (VP) and the uncoated Gunze suture (G) were used as controls. Fatty acid-coated sutures (PA80, LA80) and commercial
sutures without any drug content (V: Vicryl1, R: PGA Resorba1) were tested within the non-antimicrobial suture group. Significance levels are p<0.05 (),
p<0.01 () and p<0.001 (); n.s.: not significant, n.a.: not applicable.
https://doi.org/10.1371/journal.pone.0190912.g005
Table 2. Evaluation of the novel antimicrobial sutures using chlorhexidine or octenidine at 11 μg/cm drug compared to commercial triclosan-containing Vicryl1
Plus.
Type of antimicrobial
sutures
Viability of bacteria SEM investigation Biocompatibility Delayed drug
release
Zones of inhibition
log reduction of
adhered bacteria
log reduction of
planktonic bacteria
number of adhered
bacteria
metabolic activity
(%)
residual
content (%)
duration
(d)
initial size
(mm)
CL11 [43] +++ +++ + + + ++ ++
CP11 [43] +++ +++ ++ ++ +++ ++ ++
OL11 [44] +++ + ++ ++ + +++ +
OP11 [44] + + ++ +++ +++ +++ +
Vicryl1 Plus [43, 44] + + +++ +++ n. d. a +++ +++
a No determination of drug release, because of triclosan’s extremely low solubility in aqueous media. Referred to other in vitro studies by Ming et al. [48] and Edmiston
et al. [18], the triclosan release was rated as +++ level.
Data from our recent study (white background) concerning reduction of viable adhered, as well as bacteria in suspension, and SEM investigations were arranged next to
each other. Additionally, data from earlier studies [43, 44] are considered for evaluation regarding cytotoxicity, antimicrobial efficacy via zone of inhibition assay over
time, and the slow drug release properties (dark blue background: chlorhexidine-sutures, orange background: octenidine-sutures, and light gray background: Vicryl1
Plus suture control).
https://doi.org/10.1371/journal.pone.0190912.t002
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considerably less viable bacteria on suture surfaces than triclosan-containing suture Vicryl1
Plus. Therefore, these novel coated sutures may reduce suture-associated surgical site infection
(SSI) more effectively than otherwise possible today. SSI is still an issue in medical daily rou-
tine. Sutures can promote such infections via the so-called “wicking effect” as well as by
enabling bacteria to colonize. Sutures themselves affect bacterial adhesion, especially due to
the chemical composition of suture material, surface structure, as well as capillarity. It has
been shown that the property of sutures acts as a substrate for adhering bacteria can be corre-
lated with the rate of infection [9]. Viable adhering bacteria form biofilms on suture surfaces
by proliferation. These biofilms are even detectable on sutures in “culture-negative” SSI, a spe-
cial form of wound infection in which no bacterial pathogens could be cultured using conven-
tional diagnostic methods. [11] Antimicrobial-coated sutures also inhibit adhering bacteria
and can be an established adjunctive aspect in reducing SSI [15] and thus interrupt this infec-
tion pathway.
The zone of inhibition assay showed a multispecies efficacy of novel coated sutures against
the five tested relevant bacterial species. Therefore, a potential inhibition of clinical relevant
pathogens is assumed. The efficacy is mainly dependent on the type of drug used for coating
(chlorhexidine or octenidine) but also–to minor degree–on the drug carrier (laurate or palmi-
tate). Overall, the antibacterial efficacy of coated sutures was comparably to the clinically most
relevant S. aureus species. Therefore, S. aureus was used to investigate the bacterial adhesion in
further detail. The inhibition zones indicated a sustaining broad-activity over the tested 48
hours. The amount of drug release is directly indicated by the size of inhibition zones. The
suture‘s drug release persists for more than two days. That “fits” well with the description in lit-
erature [43, 44] antimicrobial efficacy lasting for nine days using octenidine coatings and for
up to five days with chlorhexidine coatings. Novel coated suture materials protected broadly
against microbes for the critical period of 48 hours after surgery, which is necessary to avoid
SSI. Moreover, there is a high local efficacy against problematic MRSA infections.
Structural investigations by SEM of coated sutures showed uniformly distributed antimi-
crobial coatings on surfaces around the multifilament structure. Dependent on the type of
fatty acid carrier, there was a detectable difference concerning the level of roughness. For lauric
acid coatings, the fine structure of suture filaments was preserved. Coatings containing pal-
mitic acid seemed to laminate filament strands resulting in a high degree of roughness, proba-
bly an effect of the presence of longer hydrocarbon chains. This observation is comparable to
commercial sutures, such as Vicryl1, PGA Resorba1, and Vicryl1 Plus. Especially, absorb-
able braided sutures are using coatings consisting of calcium stearate formulations to improve
handling [49] and to smoothen the surface. Thus, the tissue damage by braided sutures during
suturing, the so-called “sawing action” is reduced [50]. Calcium stearates consist of stearic
acid, a fatty acid with an 18-carbon chain that is comparable to palmitic acid.
Table 3. Rating levels used for comparative antimicrobial suture evaluation.
Sutures properties that are compared Rating levels
+ ++ +++
Viability of bacteria log reduction of bacteria  0.3  0.6  0.9
SEM investigation number of adhered bacteria < 50 50–200 > 200
Biocompatibility metabolic activity  60%  70%  80%
Delayed drug release residual content after 96 h  10%  40%  60%
Zones of inhibition initial size after 24 h  1 mm  4 mm  10 mm
days of duration  1 d  4 d  8 d
https://doi.org/10.1371/journal.pone.0190912.t003
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SEM pictures of inoculated sutures with 1.0 x 108 cfu/ml S. aureus suspension over 3 h indi-
cated numerous adhering bacteria on all suture surfaces whether coated with antimicrobial
agents or not. Bacterial adherence seems to be independent from substance, drug carrier, sur-
face roughness, or drug concentration. Especially, the gaps between single filaments of
uncoated or laurate-containing sutures represent areas which were colonized by bacteria lead-
ing to a pearl chain arrangement (Fig 3, e.g. Gunze, CL33 and LA80). Adhering bacteria on
surgical sutures represent a potential risk for wound infections and need effective inactivation
to counteract infections. The sutures’ capillarity acts as a door opener for pathogens to pene-
trate into wounds as these microorganisms may trigger infection [51].
Some authors detected biofilm formation of bacteria grown on suture surfaces [52]. Further
SEM pictures of inoculated suture samples also potentially demonstrated the production of lit-
tle extracellular matrix around adhered bacteria, indicating the beginning of biofilm formation
on sutures. Adhered bacteria were detached by sonication and viable bacteria were quantified
afterwards. A strong inhibition of initially adhered bacteria during a short period of incubation
was detected for the novel antimicrobial sutures. Therefore, an inhibiting effect on biofilm for-
mation on sutures can be strongly expected. Sutures using lauric acid showed a higher number
of adhering bacteria than those using the palmitic acid carriers. This conspicuousness was con-
firmed by the bacterial adhesion assay, proving higher numbers of viable adhering bacteria for
lauric acid containing sutures.
The bacterial adhesion assay indicated a drastic log reduction of viable adhered bacteria on
novel antimicrobially coated sutures. Compared to the weak log reduction of Vicryl1 Plus the
bacterial inhibition by contact with the novel antimicrobial sutures can be up to 12-times
higher dependent on the kind of substance, drug carrier, and drug concentration employed.
We suggest that the adhesion of bacteria could not be avoided by numbers via antimicrobial
coatings. However, antimicrobial agents inside novel coatings significantly reduced the num-
ber of viable adhering bacteria in our experiments. Novel coated sutures may inhibit bacterial
proliferation on suture surfaces and thus inhibit the initial biofilm formation. Consequently,
novel chlorhexidine- and octenidine-coated sutures may have a higher ability to prevent SSI
related to suture material than Vicryl1 Plus. This effect could be limited by the numbers of
microbes inside the incision or on the threads, and the sensitivity of bacteria against the type
of drugs used in the coating layers. Sutures coated with fatty acid carriers only showed a
slightly higher number of viable adhered bacteria compared to Gunze sutures without any
coating (G). Especially lauric acid coatings (LA80) seem to attract adhering bacteria more than
palmitic acid suture (PA80). Thus, laurates are presumably more suitable as drug carriers than
palmitates to achieve low bacterial adherence.
Regarding the ultrasound treatment to release adhered bacteria, sonication is a competitive
process between releasing and killing adhering bacteria, dependent on the duration of sonica-
tion [53]. Therefore, a short sonication time of 1 min was chosen, resulting in a low killing rate
versus a detectable viable bacterial release. In combination with vortexing an increased soft
release could be achieved [54]. Since all sutures were treated equally, sonication and vortexing
is a meaningful process to release bacteria. Antimicrobial coatings are not able to reduce bacte-
rial adhesion in general. However, they are an effective method to inactivate viable adhering
bacteria [47].
Bacterial growth was investigated by incubation of S. aureus suspensions including coated
and uncoated suture samples. Planktonic bacteria were highly inhibited by chlorhexidine- or
octenidine-coated sutures compared to sutures without antimicrobial coating. In comparison
to the commercially available triclosan suture Vicryl1 Plus, a much higher effectiveness of
bacterial reduction was demonstrated for all types of tested chlorhexidine sutures, as well as
for the higher concentrated octenidine sutures. In addition, lower concentrations of octenidine
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in sutures showed a similar inhibition effect to that obtained by Vicryl1 Plus. The efficacy
was strongly dependent on the drug type, presumably in regard to its individual solubility and
therefore differing drug release from suture coatings. Solubility in aqueous media was
extremely low for triclosan, higher for octenidine and highest for chlorhexidine. We hypothe-
size that free drug molecules combined with a certain drug concentration would be necessary
for an effective antimicrobial activity against bacteria.
Siedenbiedel and Tiller described multiple mechanism for antimicrobial surfaces, the killing
effect on surrounding pathogens by drug releasing surfaces and the direct contact inactivation
on surfaces, as well as a repelling effect on microorganisms [55]. We hypothesize that antimi-
crobial sutures based on fatty acid drug carriers inhibit surrounding pathogens by drug release,
and on the other hand inhibit viable pathogens by direct contact with drug molecules during
attachment on surfaces. We also presume that bacterial inhibition is dominated by surface
inactivation or rather bactericidal effects on surfaces, due to the highly reduced number of via-
ble adhered bacteria.
The present study has some important limitations: Although, the broad antibacterial effi-
cacy of novel coated sutures has been shown in a zone of inhibition assay, only the clinically
most relevant pathogen Staphylococcus aureus (S. aureus ATTC149230™) was used for the
bacterial adhesion assay. Staphylococci species are the most common pathogens responsible
for wound infections and a variety of implant-associated infection [40, 56]. However, to iden-
tify the full potential of this approach, further research has to investigate bacterial adhesion by
using other relevant strains. Nevertheless, the high multispecies antimicrobial efficacy via inhi-
bition zones presumably also indicates high degrees of inactivation of other adhering bacteria.
Our monospecies microbiological setup for investigation of bacterial adhesion is able to pro-
vide answers to the potential effect on initially adhered staphylococci and thus results in the
potential to inhibit the following biofilm formation. Data was collected advantageous without
any interference by interactions between different species. A further limitation is the sonica-
tion itself as a competitive process between detachment of bacteria and potential harm. Due to
methodological constraints, the absolute number of bacteria adhering to suture surfaces could
not be detected. The counts of cfu from surface-released bacteria only represent the viable con-
tent of adhering bacteria. Moreover, when using SEM pictures for visualization of adhering
bacteria, it is not possible to distinguish between viable and inactivated bacteria. The fluores-
cence microscopy technique combined with a live/dead bacterial staining assay could solve
this problem in future studies.
In summary, the zone of inhibition assay documented a bacterial multispecies efficacy over
48 hours. SEM investigations showed uniformly covered suture surfaces by coating and differ-
ent roughness dependent on the type of fatty acid carrier. Furthermore, adhering S. aureus
were found on each kind of tested suture, whether coated with antimicrobial substances or
not. The number of viable S. aureus adhering on suture control groups was extremely high,
without any drug and on the antimicrobial control Vicryl1 Plus. Therefore, coated sutures
presumably could not avoid bacterial adhesion itself. At the same time, novel coated sutures
using chlorhexidine or octenidine inhibited adhered S. aureus significantly. Chlorhexidine-
laurate suture (CL11) shows the lowest remaining number of viable adhered bacteria, despite
an extremely high concentration of S. aureus inoculation. These bacteria are critical for the
onset of local infections, thus this suture has the highest potential to further reduce the rates of
SSI. Consequently, CL11 best fulfills the medical need and we recommend this suture type
compared to Vicryl1 Plus as an optimal surgical supplement to reduce wound infections. Fur-
thermore, planktonic bacteria in suspension were also drastically inhibited by the novel coated
sutures chlorhexidine-laurate, chlorhexidine-palmitate and octenidine-palmitate at 11 μg/cm.
Octenidine-laurate at 11 μg/cm exceptionally showed a similar number of adhered bacteria to
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Vicryl1 Plus, which nevertheless represents a reduction of 0.5 log compared to uncoated
Gunze sutures. Octenidine-containing sutures at 11 μg/cm (OL11) can also be helpful in appli-
cations where a longer-lasting drug release may be necessary, e.g. when infections already exist
during septic surgery.
Novel coated sutures in former studies showed excellently adjustable antimicrobial efficacy
and release kinetics, lasting some days for chlorhexidine formulations and up to nine days for
octenidine coatings. Dependent on the kind of drug, it could therefore possibly be useful to
distinguish between two fields of application: on the one hand, a long-term drug release, e.g.
for wound closure during septic surgery. On the other hand, applications with a shorter drug
release, e.g. for infection prophylaxis in common surgery.
The present study fundamentally demonstrated a much higher inactivation of viable adher-
ing bacteria through novel antimicrobially coated sutures and thus, presumably, a much higher
potential to interrupt the”wicking effect” compared to Vicryl1 Plus. Therefore, we suppose
that the novel sutures have a higher potential to avoid suture-associated SSI. Pre-clinical stud-
ies, followed by clinical investigations are necessary to demonstrate their ability to avoid SSI in
vivo and prove their safety. Novel antimicrobial sutures using chlorhexidine or octenidine at
11 μg/cm drug content may pose an alternative in case of triclosan resistance, or to extend the
active substances clinically used on antimicrobial sutures. This should give surgeons an addi-
tional effective tool to react to complex pathogen milieus and resistances.
Conclusions
In this study, we found that the novel chlorhexidine- and octenidine-coated sutures are effec-
tive against multiple bacterial species over the critical period of 48 hours after surgery. The
analysis in detail for S. aureus revealed that antimicrobial sutures at 11 μg/cm drug content
demonstrate superior bactericidal properties against adhering S. aureus compared to commer-
cial triclosan-containing Vicryl1 Plus. Especially, the chlorhexidine-laurate coating (CL11)
shows the highest efficacy to minimize the number of adhered as well as planktonic bacteria.
This coating provides a high drug release in the first, clinically most relevant 48 h after suture
application and is–in addition–highly biocompatible. Therefore, this coating type best meets
the medical needs and should be recommended for potential clinical application. The high
reduction of viable adhering bacteria on this novel coated suture is a promising approach to
improve prevention of surgical site infections in routine surgery. These results encourage fur-
ther pre-clinical and clinical trials to confirm safety and efficacy of this coating technology in
vivo.
Acknowledgments
We would like to thank Dr. K.-H. Sorg (Resorba Wundversorgung GmbH, Germany) for his
supply with PGA Resorba1 sutures and raw PGA material (Gunze Limited, Japan). We
would like to express our special thanks to S. Schnell-Witteczek (Institute of Medical Engineer-
ing, Technical University of Munich (IMETUM), Garching) for her great assistance in scan-
ning electron microscopy. Many thanks to Mr. F. Seidl (M.A. Interpreting and Translating)
for his kind support in scientific English.
Author Contributions
Conceptualization: Andreas Obermeier, Matthias Schieker, Rainer Burgkart.
Data curation: Andreas Obermeier, Jutta Tu¨bel, Dominik Pfo¨rringer, Barbara Kiefel.
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
PLOS ONE | https://doi.org/10.1371/journal.pone.0190912 January 9, 2018 16 / 20
Formal analysis: Andreas Obermeier, Jochen Schneider, Heinrich Mu¨hlhofer, Peter Foehr,
Christina Kra¨mer.
Funding acquisition: Axel Stemberger, Rainer Burgkart.
Investigation: Andreas Obermeier.
Methodology: Andreas Obermeier, Norbert Harrasser, Jutta Tu¨bel, Dominik Pfo¨rringer, Peter
Foehr.
Project administration: Andreas Obermeier, Heinrich Mu¨hlhofer, Matthias Schieker, Rainer
Burgkart.
Resources: Rainer Burgkart, Ru¨diger von Eisenhart-Rothe.
Software: Norbert Harrasser, Constantin von Deimling.
Supervision: Heinrich Mu¨hlhofer, Axel Stemberger, Rainer Burgkart, Ru¨diger von Eisenhart-
Rothe.
Validation: Andreas Obermeier, Jochen Schneider, Norbert Harrasser, Heinrich Mu¨hlhofer,
Dominik Pfo¨rringer, Constantin von Deimling, Peter Foehr, Christina Kra¨mer, Axel Stem-
berger, Matthias Schieker.
Visualization: Andreas Obermeier, Jochen Schneider, Norbert Harrasser, Jutta Tu¨bel, Con-
stantin von Deimling, Barbara Kiefel, Christina Kra¨mer, Rainer Burgkart.
Writing – original draft: Andreas Obermeier.
Writing – review & editing: Andreas Obermeier, Jochen Schneider, Norbert Harrasser, Jutta
Tu¨bel, Heinrich Mu¨hlhofer, Dominik Pfo¨rringer, Constantin von Deimling, Peter Foehr,
Barbara Kiefel, Christina Kra¨mer, Axel Stemberger, Matthias Schieker, Rainer Burgkart,
Ru¨diger von Eisenhart-Rothe.
References
1. Hranjec T, Swenson BR, Sawyer RG. Surgical site infection prevention: how we do it. Surgical infec-
tions. 2010; 11(3):289–94. Epub 2010/06/04. https://doi.org/10.1089/sur.2010.021 PMID: 20518648;
PubMed Central PMCID: PMCPMC4702440.
2. Leaper DJ. Surgical-site infection. Br J Surg. 2010; 97(11):1601–2. Epub 2010/09/30. https://doi.org/
10.1002/bjs.7275 PMID: 20878944.
3. Baracs J, Huszar O, Sajjadi SG, Horvath OP. Surgical site infections after abdominal closure in colorec-
tal surgery using triclosan-coated absorbable suture (PDS Plus) vs. uncoated sutures (PDS II): a ran-
domized multicenter study. Surgical infections. 2011; 12(6):483–9. Epub 2011/12/07. https://doi.org/10.
1089/sur.2011.001 PMID: 22142314.
4. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. The Jour-
nal of hospital infection. 2008; 70 Suppl 2:3–10. Epub 2008/11/22. https://doi.org/10.1016/S0195-6701
(08)60017-1 PMID: 19022115.
5. Barnett TE. The not-so-hidden costs of surgical site infections. AORN J. 2007; 86(2):249–58. https://
doi.org/10.1016/j.aorn.2007.03.012 PMID: 17683722.
6. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of
wound infection. Br J Exp Pathol. 1957; 38(6):573–86. PMID: 13499821; PubMed Central PMCID:
PMCPMC2083292.
7. Gomez-Alonso A, Garcia-Criado FJ, Parreno-Manchado FC, Garcia-Sanchez JE, Garcia-Sanchez E,
Parreno-Manchado A, et al. Study of the efficacy of Coated VICRYL Plus Antibacterial suture (coated
Polyglactin 910 suture with Triclosan) in two animal models of general surgery. The Journal of infection.
2007; 54(1):82–8. Epub 2006/02/21. https://doi.org/10.1016/j.jinf.2006.01.008 PMID: 16487594.
8. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. The New England journal of medicine.
2004; 351(16):1645–54. https://doi.org/10.1056/NEJMra040181 PMID: 15483283.
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
PLOS ONE | https://doi.org/10.1371/journal.pone.0190912 January 9, 2018 17 / 20
9. Katz S, Izhar M, Mirelman D. Bacterial adherence to surgical sutures. A possible factor in suture
induced infection. Annals of surgery. 1981; 194(1):35–41. Epub 1981/07/01. PMID: 7018429; PubMed
Central PMCID: PMCPMC1345192.
10. Geiger D, Debus ES, Ziegler UE, Larena-Avellaneda A, Frosch M, Thiede A, et al. Capillary activity of
surgical sutures and suture-dependent bacterial transport: a qualitative study. Surgical infections. 2005;
6(4):377–83. https://doi.org/10.1089/sur.2005.6.377 PMID: 16433602.
11. Kathju S, Nistico L, Hall-Stoodley L, Post JC, Ehrlich GD, Stoodley P. Chronic surgical site infection due
to suture-associated polymicrobial biofilm. Surgical infections. 2009; 10(5):457–61. Epub 2009/10/09.
https://doi.org/10.1089/sur.2008.062 PMID: 19811056; PubMed Central PMCID: PMCPMC2956523.
12. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003; 2
(2):114–22. https://doi.org/10.1038/nrd1008 PMID: 12563302.
13. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001; 358(9276):135–8.
Epub 2001/07/21. PMID: 11463434.
14. Chang WK, Srinivasa S, Morton R, Hill AG. Triclosan-impregnated sutures to decrease surgical site
infections: systematic review and meta-analysis of randomized trials. Annals of surgery. 2012; 255
(5):854–9. Epub 2012/04/04. https://doi.org/10.1097/SLA.0b013e31824e7005 PMID: 22470067.
15. Edmiston CE Jr., Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimi-
crobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections? A meta-analy-
sis. Surgery. 2014; 155(2):362–3. https://doi.org/10.1016/j.surg.2013.11.002 PMID: 24433775.
16. Edmiston CE Jr., Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimi-
crobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections?: A meta-anal-
ysis. Surgery. 2013; 154(1):89–100. https://doi.org/10.1016/j.surg.2013.03.008 PMID: 23809487.
17. Wang ZX, Jiang CP, Cao Y, Ding YT. Systematic review and meta-analysis of triclosan-coated sutures
for the prevention of surgical-site infection. Br J Surg. 2013; 100(4):465–73. https://doi.org/10.1002/bjs.
9062 PMID: 23338685.
18. Edmiston CE, Seabrook GR, Goheen MP, Krepel CJ, Johnson CP, Lewis BD, et al. Bacterial adherence
to surgical sutures: can antibacterial-coated sutures reduce the risk of microbial contamination? J Am
Coll Surg. 2006; 203(4):481–9. https://doi.org/10.1016/j.jamcollsurg.2006.06.026 PMID: 17000391.
19. Ming X, Rothenburger S, Nichols MM. In vivo and in vitro antibacterial efficacy of PDS plus (polidioxa-
none with triclosan) suture. Surgical infections. 2008; 9(4):451–7. Epub 2008/08/09. https://doi.org/10.
1089/sur.2007.061 PMID: 18687027.
20. Ming X, Rothenburger S, Yang D. In vivo antibacterial efficacy of MONOCRYL plus antibacterial suture
(Poliglecaprone 25 with triclosan). Surgical infections. 2007; 8(2):201–8. https://doi.org/10.1089/sur.
2006.005 PMID: 17437365.
21. Justinger C, Schuld J, Sperling J, Kollmar O, Richter S, Schilling MK. Triclosan-coated sutures reduce
wound infections after hepatobiliary surgery—a prospective non-randomized clinical pathway driven
study. Langenbecks Arch Surg. 2011; 396(6):845–50. https://doi.org/10.1007/s00423-011-0786-7
PMID: 21455702.
22. Stone J, Gruber TJ, Rozzelle CJ. Healthcare savings associated with reduced infection rates using anti-
microbial suture wound closure for cerebrospinal fluid shunt procedures. Pediatric neurosurgery. 2010;
46(1):19–24. Epub 2010/05/11. https://doi.org/10.1159/000314053 PMID: 20453559.
23. Mingmalairak C. Antimicrobial Sutures: New Strategy in Surgical Site Infections. 2011. In: Science
against Microbial Pathogens: Communicating Current Research and Technological Advances [Inter-
net]. Formatex Research CenterMicrobiology Book Series; [313–23]. Available from: http://www.
formatex.org/microbiology3/index.html.
24. Fujita T. Antibiotic-coated surgical sutures against surgical site infection. Surgery. 2010; 147(3):464–5;
author reply 5–6. Epub 2010/02/24. https://doi.org/10.1016/j.surg.2009.04.019 PMID: 20176248.
25. Bedoux G, Roig B, Thomas O, Dupont V, Le Bot B. Occurrence and toxicity of antimicrobial triclosan
and by-products in the environment. Environmental science and pollution research international. 2012;
19(4):1044–65. https://doi.org/10.1007/s11356-011-0632-z PMID: 22057832.
26. Yazdankhah SP, Scheie AA, Hoiby EA, Lunestad BT, Heir E, Fotland TO, et al. Triclosan and antimicro-
bial resistance in bacteria: an overview. Microb Drug Resist. 2006; 12(2):83–90. Epub 2006/08/23.
https://doi.org/10.1089/mdr.2006.12.83 PMID: 16922622.
27. Aiello AE, Larson EL, Levy SB. Consumer antibacterial soaps: effective or just risky? Clin Infect Dis.
2007; 45 Suppl 2:S137–47. https://doi.org/10.1086/519255 PMID: 17683018.
28. Cooney CM. Triclosan comes under scrutiny. Environmental health perspectives. 2010; 118(6):A242.
Epub 2010/06/03. https://doi.org/10.1289/ehp.118-a242 PMID: 20515712; PubMed Central PMCID:
PMCPMC2898873.
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
PLOS ONE | https://doi.org/10.1371/journal.pone.0190912 January 9, 2018 18 / 20
29. Leaper D, Assadian O, Hubner NO, McBain A, Barbolt T, Rothenburger S, et al. Antimicrobial sutures
and prevention of surgical site infection: assessment of the safety of the antiseptic triclosan. Int Wound
J. 2011; 8(6):556–66. https://doi.org/10.1111/j.1742-481X.2011.00841.x PMID: 21854548.
30. Syed AK, Ghosh S, Love NG, Boles BR. Triclosan promotes Staphylococcus aureus nasal colonization.
MBio. 2014; 5(2):e01015. https://doi.org/10.1128/mBio.01015-13 PMID: 24713325; PubMed Central
PMCID: PMCPMC3993860.
31. Hubner NO, Matthes R, Koban I, Randler C, Muller G, Bender C, et al. Efficacy of chlorhexidine, poli-
hexanide and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polystyrene
and silicone materials. Skin Pharmacol Physiol. 2010; 23 Suppl:28–34. Epub 2010/09/21. https://doi.
org/10.1159/000318265 PMID: 20829659.
32. Hubner NO, Siebert J, Kramer A. Octenidine dihydrochloride, a modern antiseptic for skin, mucous
membranes and wounds. Skin Pharmacol Physiol. 2010; 23(5):244–58. https://doi.org/10.1159/
000314699 PMID: 20484966.
33. Muller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial
activity and cellular cytotoxicity. The Journal of antimicrobial chemotherapy. 2008; 61(6):1281–7. Epub
2008/03/28. https://doi.org/10.1093/jac/dkn125 PMID: 18364400.
34. Perez-Kohler B, Garcia-Moreno F, Brune T, Pascual G, Bellon JM. Preclinical Bioassay of a Polypropyl-
ene Mesh for Hernia Repair Pretreated with Antibacterial Solutions of Chlorhexidine and Allicin: An In
Vivo Study. PloS one. 2015; 10(11):e0142768. https://doi.org/10.1371/journal.pone.0142768 PMID:
26556805; PubMed Central PMCID: PMCPMC4640885.
35. Al-Doori Z, Goroncy-Bermes P, Gemmell CG, Morrison D. Low-level exposure of MRSA to octenidine
dihydrochloride does not select for resistance. The Journal of antimicrobial chemotherapy. 2007; 59
(6):1280–1. Epub 2007/04/19. https://doi.org/10.1093/jac/dkm092 PMID: 17439976.
36. Amalaradjou MA, Venkitanarayanan K. Antibiofilm Effect of Octenidine Hydrochloride on Staphylococ-
cus aureus, MRSA and VRSA. Pathogens. 2014; 3(2):404–16. https://doi.org/10.3390/
pathogens3020404 PMID: 25437807; PubMed Central PMCID: PMCPMC4243453.
37. Hidalgo E, Dominguez C. Mechanisms underlying chlorhexidine-induced cytotoxicity. Toxicol In Vitro.
2001; 15(4–5):271–6. PMID: 11566548.
38. Greener M. Octenidine: antimicrobial activity and clinical efficacy. Wounds UK. 2011; 7(3).
39. James GA, Swogger E, Wolcott R, Pulcini E, Secor P, Sestrich J, et al. Biofilms in chronic wounds.
Wound repair and regeneration: official publication of the Wound Healing Society [and] the European
Tissue Repair Society. 2008; 16(1):37–44. https://doi.org/10.1111/j.1524-475X.2007.00321.x PMID:
18086294.
40. Otto M. Staphylococcal biofilms. Current topics in microbiology and immunology. 2008; 322:207–28.
PMID: 18453278; PubMed Central PMCID: PMCPMC2777538.
41. Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers W. Antimicrobial prophylaxis
for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg.
2005; 189(4):395–404. https://doi.org/10.1016/j.amjsurg.2005.01.015 PMID: 15820449.
42. Kouyos RD, Metcalf CJ, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al. The path of least
resistance: aggressive or moderate treatment? Proc Biol Sci. 2014; 281(1794):20140566. https://doi.
org/10.1098/rspb.2014.0566 PMID: 25253451; PubMed Central PMCID: PMCPMC4211439.
43. Obermeier A, Schneider J, Wehner S, Matl FD, Schieker M, von Eisenhart-Rothe R, et al. Novel high
efficient coatings for anti-microbial surgical sutures using chlorhexidine in fatty acid slow-release carrier
systems. PloS one. 2014; 9(7):e101426. https://doi.org/10.1371/journal.pone.0101426 PMID:
24983633; PubMed Central PMCID: PMCPMC4077814.
44. Obermeier A, Schneider J, Fohr P, Wehner S, Kuhn KD, Stemberger A, et al. In vitro evaluation of novel
antimicrobial coatings for surgical sutures using octenidine. BMC microbiology. 2015; 15(1):186. https://
doi.org/10.1186/s12866-015-0523-4 PMID: 26404034; PubMed Central PMCID: PMCPMC4583139.
45. Fischer ER, Hansen BT, Nair V, Hoyt FH, Dorward DW. Scanning electron microscopy. Curr Protoc
Microbiol. 2012;Chapter 2:Unit 2B https://doi.org/10.1002/9780471729259.mc02b02s25 PMID:
22549162; PubMed Central PMCID: PMCPMC3352184.
46. Fox CH, Johnson FB, Whiting J, Roller PP. Formaldehyde fixation. J Histochem Cytochem. 1985; 33
(8):845–53. https://doi.org/10.1177/33.8.3894502 PMID: 3894502.
47. Gollwitzer H, Ibrahim K, Meyer H, Mittelmeier W, Busch R, Stemberger A. Antibacterial poly(D,L-lactic
acid) coating of medical implants using a biodegradable drug delivery technology. Journal of Antimicro-
bial Chemotherapy. 2003; 51(3):585–91. https://doi.org/10.1093/jac/dkg105 PubMed PMID:
WOS:000181727700013. PMID: 12615858
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
PLOS ONE | https://doi.org/10.1371/journal.pone.0190912 January 9, 2018 19 / 20
48. Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of MONOCRYL plus antibacterial suture
(Poliglecaprone 25 with triclosan). Surgical infections. 2007; 8(2):201–8. https://doi.org/10.1089/sur.
2006.005 PMID: 17437365.
49. Pillai CK, Sharma CP. Review paper: absorbable polymeric surgical sutures: chemistry, production,
properties, biodegradability, and performance. J Biomater Appl. 2010; 25(4):291–366. https://doi.org/
10.1177/0885328210384890 PMID: 20971780.
50. Zhukovskii VA. Problems and prospects for development and production of surgical suture materials.
Fibre Chemistry. 2008; 40(3):208–16. https://doi.org/10.1007/s10692-008-9039-0 PubMed PMID:
WOS:000261691200009.
51. Cooper GL, Schiller AL, Hopkins CC. Possible role of capillary action in pathogenesis of experimental
catheter-associated dermal tunnel infections. J Clin Microbiol. 1988; 26(1):8–12. Epub 1988/01/01.
PMID: 3343317; PubMed Central PMCID: PMCPMC266164.
52. Henry-Stanley MJ, Hess DJ, Barnes AM, Dunny GM, Wells CL. Bacterial contamination of surgical
suture resembles a biofilm. Surgical infections. 2010; 11(5):433–9. Epub 2010/08/03. https://doi.org/10.
1089/sur.2010.006 PMID: 20673144; PubMed Central PMCID: PMCPMC2967823.
53. Monsen T, Lovgren E, Widerstrom M, Wallinder L. In vitro effect of ultrasound on bacteria and sug-
gested protocol for sonication and diagnosis of prosthetic infections. J Clin Microbiol. 2009; 47(8):2496–
501. https://doi.org/10.1128/JCM.02316-08 PMID: 19535525; PubMed Central PMCID:
PMCPMC2725697.
54. Portillo ME, Salvado M, Trampuz A, Plasencia V, Rodriguez-Villasante M, Sorli L, et al. Sonication ver-
sus vortexing of implants for diagnosis of prosthetic joint infection. J Clin Microbiol. 2013; 51(2):591–4.
https://doi.org/10.1128/JCM.02482-12 PMID: 23135938; PubMed Central PMCID: PMCPMC3553884.
55. Siedenbiedel F, Tiller JC. Antimicrobial Polymers in Solution and on Surfaces: Overview and Functional
Principles. Polymers. 2012; 4(1):46–71. https://doi.org/10.3390/polym4010046 PubMed PMID:
WOS:000313355800004.
56. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin
Infect Dis. 2001; 33(9):1567–72. https://doi.org/10.1086/323130 PMID: 11577378.
Inhibition of adhered bacteria on novel antimicrobial sutures against SSI
PLOS ONE | https://doi.org/10.1371/journal.pone.0190912 January 9, 2018 20 / 20
